SUMMARY Thirteen newborn infants, 8 term and 5 preterm (gestational age 31 to 36 weeks), were treated for between 3 and 7 days with gentamicin and ampicillin or cloxacillin because of suspected bacterial infection. The dosage of gentamicin was carefully monitored by serum concentration assays. Urinary alanine aminopeptidase, urinary P2-microglobulin, serum urea, and serum f2-microglobulin were measured during and after the end of treatment to detect signs of renal toxicity. Levels of urinary aminopeptidase increased in 12 of them, indicating damage to the cells of the proximal tubuli. Changes in urinary 32-microglobulin followed the normal physiological course seen in neonates after birth. Serum levels of urea and 32-microglobulin did not indicate any drugassociated depression of glomerular filtration rate.
In recent years it has been demonstrated that in most adults the kidneys are affected by therapeutic doses of gentamicin. After only one injection there is an increase in the urine of enzymes from renal tubular cells-for example, alanine aminopeptidase (AAP).' In many patients there is also an increase in the urinary excretion of ,B2-microglobulin, indicating a reduced reabsorptive capacity of the proximal tubuli.2 Moreover, a small but significant decrease of glomerular filtration rate (GFR), as measured by 51chrome-EDTA clearance, has been demonstrated.2 This decrease is accompanied by a significant increase in serum P2-microglobulin, but not in serum creatinine.
Aminoglycoside-associated nephrotoxicity is considered to be rare in infants, but it is difficult to assess renal function and to determine which changes are drug associated and which are dependent on other factors.3 5 Clearance determinations may be difficult to perform in neonates. Serum urea, commonly used to approximate GFR, is influenced by the increased protein intake after birth.6 Furthermore, renal function in neonates alters according to gestational age6 and pronounced changes in both glomerular and tubular function occur after birth.6
The aim of this study was to search for signs of renal toxicity in neonates treated with gentamicin. Levels of urinary AAP and urinary 3 2-microglobulin were used to evaluate effects on the proximal tubuli.
Levels of serum urea and serum 32-microglobulin were measured to detect major changes in GFR.
Patients
Thirteen neonates, 6 boys and 7 girls, were treated with gentamicin. Eight were born at a gestational age of 37 to 42 weeks (term). Four were born at a gestational age of 34 to 36 weeks, and one was born at 31 weeks. The gentamicin treatment started within 24 hours of birth in 6 patients, between the 2nd and 5th day of life in 6 patients, and on the 13th day of life in one. Indications for treatment were febrile mother at birth (2 patients), purulent amniotic fluid (1), cutaneous abscess (1), and suspicion of septicaemia (9) . Septicaemia was suspected because of cerebral irritation and cyanosis (4 patients), hyperthermia (3), hypothermia (1), and impaired respiration (1).
Gentamicin was given intramuscularly in a dose of 2.5 mg/kg every 18th hour. The dose was adjusted according to the serum concentrations of gentamicin assayed daily or every other day. Blood was taken immediately before (peak level) and one hour after (trough level) the injection. Peak levels below 4 mg/l were considered subtherapeutic requiring an increase in the dose.
The patient with cutaneous abscesses was given cloxacillin and the other patients received ampicillin in combination with gentamicin. In one patient Staphylococcus aureus was isolated from the blood. His condition soon improved on treatment with gentamicin and ampicillin, but from the 4th day only cloxacillin was given. One patient had a serious bacterial infection but blood cultures were negative. From the urine a Klebsiella sp. was isolated (bladder puncture) and he had a thrombocytopenia (thrombocytes 26 x 109/l) when treatment started. His condition soon improved with treatment which was given for 6 days. In the other 11 patients, all of whom improved rapidly, the suspicion of septicaemia was not verified by cultures and gentamicin treatment was stopped after 3 to 7 days. Methods AAP in the urine was analysed with a method using L-alanine-p-nitroanilid as substrate at 37°C. Since urine was collected as random samples, urinary AAP and urinary P2-microglobulin were related to urinary creatinine to eliminate differences in urinary flow.
Results
The trough serum levels of gentamicin were below 1 mg/l in most patients during the entire treatment time. Only on a few occasions were trough levels of between 1 and 2 mg/l observed. The peak levels of gentamicin were below 4 mg/l on one occasion in each of 3 patients. Apart from this the peak serum levels ranged from 4-3 to 8 mg/l and were generally between 5 and 6 mg/l.
In the 8 term infants treated with gentamicin, the median activity of urinary AAP was 0-07 (range 0-06-0-14) mkat/mol creatinine before the start of treatment. In all of them the AAP activity increased during treatment. With only one exception did the AAP activity during treatment exceed the upper reference limit of 0 22 mkat/mol creatinine (Figure, left). After treatment ended the AAP activity decreased but did not reach the pretreatment level during the observation period. In the 4 infants born at a gestational age of 34 to 36 weeks the AAP activity increased during the gentamicin treatment (Figure, right) . In one of these patients, in whom gentamicin serum levels were no higher than in the others, a pronounced increase in AAP activity was present after only 2 days of treatment, followed by a decrease the next day despite continued treatment. In the patient born at a gestational age of 31 weeks, the AAP activity was high before treatment started but fell during it (Figure, right) .
The urinary levels of 32-microglobulin varied considerably (range 0-13-14.8 g/mol creatinine) before the start of treatment.
Apart from 2 term infants who had low levels within 2 days of birth, the variations could be explained by differences in gestational age and age at start of treatment. The changes that occurred in urinary 32-microglobulin during the gentamicin treatment ( Figure) 
